Kerry L. Burnstein - Publications

University of Miami, Coral Gables, FL 
Cell Biology, Pharmacology, Oncology

40 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2019 Zhao N, Peacock SO, Lo CH, Heidman LM, Rice MA, Fahrenholtz CD, Greene AM, Magani F, Copello VA, Martinez MJ, Zhang Y, Daaka Y, Lynch CC, Burnstein KL. Arginine vasopressin receptor 1a is a therapeutic target for castration-resistant prostate cancer. Science Translational Medicine. 11. PMID 31243151 DOI: 10.1126/scitranslmed.aaw4636  0.56
2018 Magani F, Bray ER, Martinez MJ, Zhao N, Copello VA, Heidman L, Peacock SO, Wiley DJ, D'Urso G, Burnstein KL. Identification of an oncogenic network with prognostic and therapeutic value in prostate cancer. Molecular Systems Biology. 14: e8202. PMID 30108134  0.56
2017 Magani F, Peacock SO, Rice MA, Martinez MJ, Greene AM, Magani PS, Lyles R, Weitz JR, Burnstein KL. Targeting AR Variant-coactivator Interactions to Exploit Prostate Cancer Vulnerabilities. Molecular Cancer Research : McR. PMID 28811363 DOI: 10.1158/1541-7786.MCR-17-0280  0.56
2016 Rice MA, Ishteiwy RA, Magani F, Udayakumar T, Reiner T, Yates TJ, Miller P, Perez-Stable C, Rai P, Verdun R, Dykxhoorn DM, Burnstein KL. The microRNA-23b/-27b cluster suppresses prostate cancer metastasis via Huntingtin-interacting protein 1-related. Oncogene. PMID 26898757 DOI: 10.1038/onc.2016.6  0.32
2014 Fahrenholtz CD, Greene AM, Beltran PJ, Burnstein KL. A novel calcium-dependent mechanism of acquired resistance to IGF-1 receptor inhibition in prostate cancer cells. Oncotarget. 5: 9007-21. PMID 25344862 DOI: 10.18632/oncotarget.2346  0.36
2014 Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, ... ... Burnstein KL, et al. VAV3 mediates resistance to breast cancer endocrine therapy. Breast Cancer Research : Bcr. 16: R53. PMID 24886537 DOI: 10.1186/bcr3664  0.32
2014 Jaganathan A, Chaurasia P, Xiao GQ, Philizaire M, Lv X, Yao S, Burnstein KL, Liu DP, Levine AC, Mujtaba S. Coactivator MYST1 regulates nuclear factor-κB and androgen receptor functions during proliferation of prostate cancer cells. Molecular Endocrinology (Baltimore, Md.). 28: 872-85. PMID 24702180 DOI: 10.1210/me.2014-1055  0.32
2014 Fahrenholtz CD, Rick FG, Garcia MI, Zarandi M, Cai RZ, Block NL, Schally AV, Burnstein KL. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 111: 1084-9. PMID 24395797 DOI: 10.1073/pnas.1323102111  0.32
2013 Fahrenholtz CD, Beltran PJ, Burnstein KL. Targeting IGF-IR with ganitumab inhibits tumorigenesis and increases durability of response to androgen-deprivation therapy in VCaP prostate cancer xenografts. Molecular Cancer Therapeutics. 12: 394-404. PMID 23348048 DOI: 10.1158/1535-7163.MCT-12-0648  0.36
2013 Wu F, Peacock SO, Rao S, Lemmon SK, Burnstein KL. Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth. The Journal of Biological Chemistry. 288: 5463-74. PMID 23281476 DOI: 10.1074/jbc.M112.390963  0.56
2012 Ishteiwy RA, Ward TM, Dykxhoorn DM, Burnstein KL. The microRNA -23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. Plos One. 7: e52106. PMID 23300597 DOI: 10.1371/journal.pone.0052106  0.32
2012 Catanuto P, Fornoni A, Pereira-Simon S, Wu F, Burnstein KL, Xia X, Conti F, Lenzi A, Elliot S. In vivo 17β-estradiol treatment contributes to podocyte actin stabilization in female db/db mice. Endocrinology. 153: 5888-95. PMID 23070549 DOI: 10.1210/en.2012-1637  0.32
2012 Peacock SO, Fahrenholtz CD, Burnstein KL. Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival. Molecular Endocrinology (Baltimore, Md.). 26: 1967-79. PMID 23023561 DOI: 10.1210/me.2012-1165  0.56
2012 Rao S, Lyons LS, Fahrenholtz CD, Wu F, Farooq A, Balkan W, Burnstein KL. A novel nuclear role for the Vav3 nucleotide exchange factor in androgen receptor coactivation in prostate cancer. Oncogene. 31: 716-27. PMID 21765461 DOI: 10.1038/onc.2011.273  0.32
2011 Rosenblatt AE, Garcia MI, Lyons L, Xie Y, Maiorino C, Désiré L, Slingerland J, Burnstein KL. Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocrine-Related Cancer. 18: 207-19. PMID 21118977 DOI: 10.1677/ERC-10-0049  0.32
2010 Flores O, Burnstein KL. GADD45gamma: a new vitamin D-regulated gene that is antiproliferative in prostate cancer cells. Endocrinology. 151: 4654-64. PMID 20739400 DOI: 10.1210/en.2010-0434  1
2010 Flores O, Wang Z, Knudsen KE, Burnstein KL. Nuclear targeting of cyclin-dependent kinase 2 reveals essential roles of cyclin-dependent kinase 2 localization and cyclin E in vitamin D-mediated growth inhibition. Endocrinology. 151: 896-908. PMID 20147522 DOI: 10.1210/en.2009-1116  1
2009 Rosenblatt AE, Burnstein KL. Inhibition of androgen receptor transcriptional activity as a novel mechanism of action of arsenic. Molecular Endocrinology (Baltimore, Md.). 23: 412-21. PMID 19131511 DOI: 10.1210/me.2008-0235  0.32
2009 Lee JG, Zheng R, McCafferty-Cepero JM, Burnstein KL, Nanus DM, Shen R. Endothelin-1 enhances the expression of the androgen receptor via activation of the c-myc pathway in prostate cancer cells. Molecular Carcinogenesis. 48: 141-9. PMID 18623111 DOI: 10.1002/mc.20462  0.32
2008 Lyons LS, Rao S, Balkan W, Faysal J, Maiorino CA, Burnstein KL. Ligand-independent activation of androgen receptors by Rho GTPase signaling in prostate cancer. Molecular Endocrinology (Baltimore, Md.). 22: 597-608. PMID 18079321 DOI: 10.1210/me.2007-0158  0.84
2006 Lu NZ, Wardell SE, Burnstein KL, Defranco D, Fuller PJ, Giguere V, Hochberg RB, McKay L, Renoir JM, Weigel NL, Wilson EM, McDonnell DP, Cidlowski JA. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacological Reviews. 58: 782-97. PMID 17132855 DOI: 10.1124/pr.58.4.9  0.32
2006 Lyons LS, Burnstein KL. Vav3, a Rho GTPase guanine nucleotide exchange factor, increases during progression to androgen independence in prostate cancer cells and potentiates androgen receptor transcriptional activity. Molecular Endocrinology (Baltimore, Md.). 20: 1061-72. PMID 16384856 DOI: 10.1210/me.2005-0346  0.84
2005 Balkan W, Burnstein KL, Schiller PC, Perez-Stable C, D'Ippolito G, Howard GA, Roos BA. Androgen-induced mineralization by MC3T3-E1 osteoblastic cells reveals a critical window of hormone responsiveness. Biochemical and Biophysical Research Communications. 328: 783-9. PMID 15694414 DOI: 10.1016/j.bbrc.2004.12.090  0.32
2004 Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES, Burnstein KL. Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene. 23: 5513-22. PMID 15077174 DOI: 10.1038/sj.onc.1207708  0.88
2004 Burnstein KL, Luetje CW. Hormone resistance: it's SMRT to fight repression. Endocrinology. 145: 1525-6. PMID 15026376 DOI: 10.1210/en.2004-0003  0.32
2003 Yang ES, Burnstein KL. Vitamin D inhibits G1 to S progression in LNCaP prostate cancer cells through p27Kip1 stabilization and Cdk2 mislocalization to the cytoplasm. The Journal of Biological Chemistry. 278: 46862-8. PMID 12954644 DOI: 10.1074/jbc.M306340200  0.88
2003 Chen TC, Holick MF, Lokeshwar BL, Burnstein KL, Schwartz GG. Evaluation of vitamin D analogs as therapeutic agents for prostate cancer Recent Results in Cancer Research. Fortschritte Der Krebsforschung. ProgrèS Dans Les Recherches Sur Le Cancer. 164: 273-288. PMID 12899529  0.32
2002 Whitlatch LW, Young MV, Schwartz GG, Flanagan JN, Burnstein KL, Lokeshwar BL, Rich ES, Holick MF, Chen TC. 25-Hydroxyvitamin D-1alpha-hydroxylase activity is diminished in human prostate cancer cells and is enhanced by gene transfer. The Journal of Steroid Biochemistry and Molecular Biology. 81: 135-40. PMID 12137802 DOI: 10.1016/S0960-0760(02)00053-5  0.32
2002 Yang ES, Maiorino CA, Roos BA, Knight SR, Burnstein KL. Vitamin D-mediated growth inhibition of an androgen-ablated LNCaP cell line model of human prostate cancer. Molecular and Cellular Endocrinology. 186: 69-79. PMID 11850123  0.88
2001 Grad JM, Lyons LS, Robins DM, Burnstein KL. The androgen receptor (AR) amino-terminus imposes androgen-specific regulation of AR gene expression via an exonic enhancer. Endocrinology. 142: 1107-16. PMID 11181525 DOI: 10.1210/endo.142.3.8049  0.84
2000 Qadan LR, Perez-Stable CM, Schwall RH, Burnstein KL, Ostenson RC, Howard GA, Roos BA. Hepatocyte growth factor and vitamin D cooperatively inhibit androgen-unresponsive prostate cancer cell lines Endocrinology. 141: 2567-2573. PMID 10875259 DOI: 10.1210/en.141.7.2567  0.32
2000 Shen R, Sumitomo M, Dai J, Harris A, Kaminetzky D, Gao M, Burnstein KL, Nanus DM. Androgen-induced growth inhibition of androgen receptor expressing androgen-independent prostate cancer cells is mediated by increased levels of neutral endopeptidase Endocrinology. 141: 1699-1704. PMID 10803579 DOI: 10.1210/ENDO.141.5.7463  0.32
1997 Czerwiec FS, Liaw JJ, Liu SB, Perez-Stable C, Grumbles R, Howard GA, Roos BA, Burnstein KL. Absence of androgen-mediated transcriptional effects in osteoblastic cells despite presence of androgen receptors Bone. 21: 49-56. PMID 9213007 DOI: 10.1016/S8756-3282(97)00079-3  0.32
1997 Zhuang SH, Schwartz GG, Cameron D, Burnstein KL. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines Molecular and Cellular Endocrinology. 126: 83-90. PMID 9027366 DOI: 10.1016/S0303-7207(96)03974-3  0.32
1995 Burnstein KL, Maiorino CA, Dai JL, Cameron DJ. Androgen and glucocorticoid regulation of androgen receptor cDNA expression. Molecular and Cellular Endocrinology. 115: 177-86. PMID 8824893 DOI: 10.1016/0303-7207(95)03688-1  0.48
1995 Jewell CM, Webster JC, Burnstein KL, Sar M, Bodwell JE, Cidlowski JA. Immunocytochemical analysis of hormone mediated nuclear translocation of wild type and mutant glucocorticoid receptors. The Journal of Steroid Biochemistry and Molecular Biology. 55: 135-46. PMID 7495692 DOI: 10.1016/0960-0760(95)00174-X  0.32
1994 Burnstein KL, Jewell CM, Sar M, Cidlowski JA. Intragenic sequences of the human glucocorticoid receptor complementary DNA mediate hormone-inducible receptor messenger RNA down-regulation through multiple mechanisms. Molecular Endocrinology (Baltimore, Md.). 8: 1764-73. PMID 7708063 DOI: 10.1210/mend.8.12.7708063  0.32
1991 Burnstein KL, Bellingham DL, Jewell CM, Powell-Oliver FE, Cidlowski JA. Autoregulation of glucocorticoid receptor gene expression. Steroids. 56: 52-8. PMID 2020978 DOI: 10.1016/0039-128X(91)90124-E  0.32
1991 Burnstein KL, Jewell CM, Cidlowski JA. Evaluation of the role of ligand and thermal activation of specific DNA binding by in vitro synthesized human glucocorticoid receptor. Molecular Endocrinology (Baltimore, Md.). 5: 1013-22. PMID 1944294 DOI: 10.1210/mend-5-7-1013  0.32
1988 Burnstein KL, Dyer DW, Sparling PF. Preferential uptake of restriction fragments from a gonococcal cryptic plasmid by competent Neisseria gonorrhoeae Journal of General Microbiology. 134: 547-557. PMID 3141569  0.32
Show low-probability matches.